TransMedics Group (NASDAQ:TMDX) Announces Earnings Results, Beats Estimates By $0.08 EPS

TransMedics Group (NASDAQ:TMDX) released its quarterly earnings results on Wednesday. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.47) by $0.08, Fidelity Earnings reports. The company had revenue of $7.21 million during the quarter, compared to the consensus estimate of $6.67 million.

TMDX stock traded down $0.64 during trading on Friday, reaching $16.61. The company had a trading volume of 196,200 shares, compared to its average volume of 89,326. TransMedics Group has a 52 week low of $16.30 and a 52 week high of $31.54. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.55 and a quick ratio of 6.82. The business’s 50 day moving average price is $19.67.

A number of equities analysts recently issued reports on TMDX shares. Zacks Investment Research raised shares of TransMedics Group from a “sell” rating to a “hold” rating in a research note on Sunday, November 3rd. Cowen decreased their price target on shares of TransMedics Group from $40.00 to $28.00 and set an “outperform” rating for the company in a research note on Thursday. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. TransMedics Group has an average rating of “Buy” and a consensus price target of $33.00.

TransMedics Group Company Profile

TransMedics, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), an integrated, compact, portable preservation technology that addresses unmet need for organs for transplantation.

Read More: What is a bull market?

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.